Amgen Q4 Earnings: Strong Pipeline And Label Expansions Justify Buy Rating
Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...
Amgen's Broad Portfolio Strength and Wide Moat Should Protect Profits Despite Upcoming Biosimilars
Biosimilars have been on the market in Europe since 2007 but have had a larger impact on Amgen since 2019 as US exposure intensifies. Pressure on Prolia/Xgeva is coming in 2025. Amgen's pipeline had ...
Amgen Reports Fourth Quarter And Full Year 2024 Financial Results
Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable ...
pharmaphorum4d
At long last, Amgen/UCB score FDA okay for Evenity
Amgen and UCB finally have FDA approval for osteoporosis drug Evenity, two years after it was turned down by the regulator because of safety concerns. The agency approved Evenity (romosozumab ...
Business Insider22h
Meta is cutting jobs after saying it would target 'low performers.' That label can make things worse for those being laid off.
Targeting the lowest performers may be logical for the companies' bottom lines, but the publicity surrounding layoffs can give those a negative label that can compound the difficulties of being ...
Yahoo Finance4d
Amgen Inc. (AMGN)
After hours: February 7 at 7:07:51 PM EST Loading Chart for AMGN ...
Yahoo Finance4d
Amgen Inc. (AMGN)
After hours: February 7 at 7:07:51 p.m. EST ...